Canton Strategic Holdings AI Stock Analysis
Want to see CNTN full AI Analyst Report?
Canton Strategic Holdings (CNTN) AI Stock Analysis
Canton Strategic Holdings
(NASDAQ:CNTN)
The overall score of 40 reflects a high-risk, early-stage biotechnology company. The primary strength is a fortress-like, debt-free balance sheet providing a long cash runway. However, this is heavily offset by the primary risks: rapidly escalating net losses and deeply negative cash flows that are consuming capital at an increasing rate. The stock's negative P/E ratio and position below key moving averages further weigh on the score, painting a picture of a company with strong funding but significant fundamental and technical headwinds.
Canton Strategic Holdings (CNTN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $155.38M
- Dividend Yield
- ―
- Average Volume (3M)
- 756.37K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 1.35
- Revenue Growth
- ―
- EPS Growth
- 75.98%
- Country
- US
- Employees
- 12
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Canton Strategic Holdings Business Overview & Revenue Model
Company Description
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and foster...
Canton Strategic Holdings Financial Statement Overview
Summary
Financial performance is highly strained. While the balance sheet is a fortress with zero debt and $454.9M in equity, the income statement shows a $98.1M net loss and cash flow is deeply negative at -$22.2M. The escalating cash burn and lack of profitability create a high-risk profile, despite the recent emergence of initial revenue.
Income Statement
15Very NegativeBalance Sheet
70PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.50M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.50M | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -74.08M | -20.06M | -12.21M | 152.63K | -5.31M | -1.38M |
| Net Income | -98.12M | -35.92M | -12.20M | -9.32M | -8.47M | -2.21M |
Balance Sheet | ||||||
| Total Assets | 564.57M | 519.15M | 3.72M | 10.95M | 6.69M | 621.68K |
| Cash, Cash Equivalents and Short-Term Investments | 37.24M | 17.03M | 3.56M | 10.94M | 6.51M | 4,356 |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 2.17M |
| Total Liabilities | 109.67M | 121.22M | 2.41M | 1.82M | 1.14M | 5.31M |
| Stockholders Equity | 454.90M | 397.93M | 1.31M | 9.13M | 5.54M | -4.68M |
Cash Flow | ||||||
| Free Cash Flow | -22.17M | -93.70M | -10.90M | -7.30M | -6.56M | -1.09M |
| Operating Cash Flow | -22.17M | -16.13M | -10.90M | -7.30M | -6.56M | -1.09M |
| Investing Cash Flow | -138.16M | -77.57M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 195.91M | 107.17M | 3.53M | 11.72M | 13.06M | 898.75K |
Canton Strategic Holdings Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTN, the sentiment is Negative. The current price of 1.80 is below the 20-day moving average (MA) of 1.91, below the 50-day MA of 2.10, and below the 200-day MA of 2.93, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 48.15 is Neutral, neither overbought nor oversold. The STOCH value of 27.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CNTN.
Canton Strategic Holdings Risk Analysis
Canton Strategic Holdings disclosed 71 risk factors in its most recent earnings report. Canton Strategic Holdings reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksCanton Strategic Holdings Peers Comparison
Overall Rating
CSBR48Neutral
PTHS43Neutral
CRVO42Neutral
ARTV40Underperform- CNTN40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CSBR | 48Neutral | $66.53M | -60.00 | -27.88% | ― | 6.65% | -136.61% |
| PTHS | 43Neutral | $36.92M | -0.44 | -381.40% | ― | ― | ― |
| CRVO | 42Neutral | $26.78M | -0.66 | -164.95% | ― | -99.86% | 4.48% |
| ARTV | 40Underperform | $201.19M | -1.32 | -45.32% | ― | ― | 7.78% |
| CNTN | 40Underperform | $155.38M | -1.17 | -29.54% | ― | ― | 75.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CNTN | Canton Strategic Holdings, Inc. | 1.80 | -1.11 | -38.14% | |
| CRVO | Cervomed Inc. | 1.83 | -5.85 | -76.17% | |
| CSBR | Champions Oncology | 4.65 | -2.15 | -31.62% | |
| PTHS | Pelthos Therapeutics Inc. | 8.03 | -25.58 | -76.11% | |
| ARTV | Artiva Biotherapeutics, Inc. | 3.96 | 0.71 | 21.85% |
Canton Strategic Holdings Corporate Events
Canton Strategic Holdings Launches Tokenized Stock Trading on Canton Network
PositiveOn November 4, 2026, Canton Strategic Holdings completed the first trades of its issuer-sponsored tokenized common stock on TSV, a permissioned venue on the Canton Network. Fairmint, the company’s SEC-registered transfer agent, recorded the shares, w...
Canton Strategic Launches Tokenized Equity Trading on TSV
PositiveOn October 29, 2026, Canton Strategic Holdings announced an agreement with TSV LLC to enable trading of its common stock as tokenized shares on TSV, a regulated venue for tokenized U.S. NMS equities on the Canton Network. The issuer-sponsored tokeniz...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026